Glaucoma
Conditions
Interventions
None listed
Sponsors
Santen Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Twenty eight patients who persisted over 180-days continuous visit in the phase 2 of preceding glaucoma persistence rate study conducted by Santen
Exclusion criteria
Exclusion criteria: Not applicable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure change between pre and post persisting visit | — |
Countries
Japan
Contacts
Public ContactNaomi Otsuka
Santen Pharmaceutical Co., Ltd. Japan Medical Affairs Group, Development Management Department, Japan Business
Outcome results
None listed